ClinicalTrials.gg
CompletedNCT01710670Updated Oct 11, 2018

A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects

A Phase 1 interventional study of Brivaracetam and Ethanol in Healthy Volunteers, sponsored by UCB Pharma SA. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-11.

Sponsored by UCB Pharma SA (part of UCB S.A.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

To evaluate if Brivaracetam (BRV) influences the psychomotor and cognitive impairing effects of Ethanol

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Brivaracetam
  • Ethanol
  • Pharmacodynamics
  • Pharmacokinetic
  • Interaction
03

In context

Lead sponsor

UCB Pharma SA is the lead sponsor of 28 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers with the age between 18 and 55 years old

Exclusion criteria

Exclusion Criteria:

  • Subject has participated or is participating in any other clinical studies of drug or another investigational medical product within the last 3 months or has participated in 4 or more Investigational Medicinal Product (IMP) studies within 1 year prior to screening
  • Subject is not healthy (eg, taking any drug treatments except use of Paracetamol, excessive amount of alcohol, cigarettes, caffeine consumption, having a positive drug / alcohol abuse, having abnormal safety parameters)
  • Subject has not been vaccinated for hepatitis
  • Subjects has consumed any grapefruits, grapefruits juice, grapefruit-containing products or star fruit within 14 days prior to dosing or not able to refrain from these products during the study
  • Subject has Ethanol intolerance
  • Subject has a known to any components of the Investigational Medicinal Product (IMP)
  • Subject has made a blood donation or a comparable blood loss (500 ml) within the last 3 months prior to screening
  • subject is an employee of the investigator or study center or subject is a family member of an employee working in the respective study center or of the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Ethanol + Brivaracetam

    Treatment A: Ethanol + Brivaracetam

    Drug: Brivaracetam · Other: Ethanol

  • Experimental
    Ethanol Placebo + Brivaracetam

    Treatment B: Ethanol Placebo + Brivaracetam

    Drug: Brivaracetam · Other: Ethanol Placebo

  • Experimental
    Ethanol + Brivaracetam Placebo

    Treatment C: Ethanol + Brivaracetam Placebo

    Other: Ethanol · Other: Brivaracetam Placebo

Interventions

  • Strength: 200 mg (4 x 50 mg) Form: oral tablet Frequency: single dose Description: All subjects will receive a single oral dose of Brivaracetam (BRV) 200 mg, given as 50 mg tablets times 4 followed by an adequate volume of water (approximately 200 ml) in 2 of the 3 crossover periods. This dose will be administered 30 minutes after the initiation of the Ethanol / Ethanol Placebo infusion on Day 1.

  • OtherEthanol

    Form: intravenous infusion Frequency: continuous infusion Description: The ethanol infusion rate is initially based on weight, height, age, and sex. Subsequently, the infusion rate will be adjusted based on Breath Ethanol Measurements to maintain Breath Ethanol Levels (and by extension, blood ethanol levels) of 0.6 g / L.

  • OtherBrivaracetam Placebo

    In 1 of the 3 crossover periods, all subjects will receive 4 Placebo tablets to match the 50 mg Brivaracetam (BRV) tablets. The Placebo tablet will contain the same excipients as the BRV tablets but without BRV.

  • OtherEthanol Placebo

    In 1 crossover period subjects will receive Ethanol Placebo (5% glucose). On Day 1, the continuous infusion of Ethanol Placebo will begin with a 30 minute Loading Phase prior to administration of Brivaracetam (BRV) / BRV Placebo and will continue until 5 hours after administration of BRV/BRV Placebo. During the first 10 minutes, the infusion will be accompanied by an infusion of 5% Glucose via the same line in order to mask the sensation at the beginning of the Ethanol infusion.

06

What researchers measure

Primary outcomes

  1. Saccadic Eye Movements from 60 minutes Pre-Dose up to 10 hours Post-Dose

    Average values of Latency (reaction time), Saccadic Peak Velocity, and Inaccuracy (difference between stimulus angle and corresponding saccade in percentages) will be calculated for all artifact-free saccades.

    Time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose

  2. Smooth pursuit eye movements from 60 minutes Pre-Dose up to 10 hours Post-Dose

    The time during which the eyes are in smooth pursuit of the target will be calculated for each frequency and expressed as a percentage of stimulus duration. The average percentage of smooth pursuit for all stimulus frequencies will be used as a parameter.

    Time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose

  3. Adaptive tracking from 60 minutes Pre-Dose up to 10 hours Post-Dose

    Performance will be scored after a fixed period of 3.5 minutes and reflected visuo motor control and vigilance. The average performance scores will be used in the analysis.

    Time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose

  4. Body sway from 60 minutes Pre-Dose up to 10 hours Post-Dose

    The body sway meter allows measurement of body movements in a single plane, providing a measure of postural stability. (antero-posterior sway in mm / 2 minutes)

    Time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose

  5. Visual Analog Scales for Mood From 60 minutes Pre-Dose up to 10 hours Post-Dose

    Visual Analog Scales according to Bond and Lader

    Time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose

  6. Visual Analog Scale for alcohol intoxication From 60 minutes Pre-Dose up to 10 hours Post-Dose

    The scale consists of a 10 cm line anchored on the left end by "sober" and on the right end by "drunk." Subjects mark a point on the line that best represents their subjective state corresponding to the condition tested. The result is a distance calculated from the mark on the line.

    Time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose

  7. Visual Verbal Learning Test from 1.5 hours Post-Dose up to 6 hours Post-Dose

    Immediate recall, immediate recognition, delayed recall, and delayed recognition to evaluate memory

    Time frame: From 1.5 hours Post-Dose up to 6 hours Post-Dose

  8. Visual Analog Scales for Alertness From 60 minutes Pre-Dose up to 10 hours Post-Dose

    Visual Analog Scales according to Bond and Lader

    Time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose

  9. Visual Analog Scales for Calmness From 60 minutes Pre-Dose up to 10 hours Post-Dose

    Visual Analog Scales according to Bond and Lader

    Time frame: From 60 minutes Pre-Dose up to 10 hours Post-Dose

Secondary outcomes

  1. The area under the plasma concentration-time curve from zero to infinity (AUC)

    Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.

    Time frame: From Pre-Dose (- 5 minutes) to 36 hours Post-Dose

  2. The area under the plasma concentration-time curve from zero to the time of the last measured concentration above the limit of quantification [AUC(0-t)]

    Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.

    Time frame: From Pre-Dose (- 5 minutes) to 36 hours Post-Dose

  3. The maximum plasma concentration (Cmax)

    Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.

    Time frame: From Pre-Dose (- 5 minutes) to 36 hours Post-Dose

  4. The time to reach the maximum plasma concentration (tmax)

    Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.

    Time frame: From Pre-Dose (- 5 minutes) to 36 hours Post-Dose

  5. The terminal disposition rate constant (λz) with the respective terminal half-life (t1/2)

    Blood samples will be taken - 5 minutes Pre-Dose, 15, 30, and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hours Post-Dose.

    Time frame: From Pre-Dose (- 5 minutes) to 36 hours Post-Dose

  6. Serum Ethanol concentrations

    Blood samples for Ethanol concentrations will be taken - 30 minutes, - 15 and - 5 minutes Pre-Dose, then 15, 30 and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, and 10 hours Post-Dose.

    Time frame: From - 30 minutes Pre-Dose to 10 hours Post-Dose

  7. Breath Ethanol concentrations

    Blood samples for Ethanol concentrations will be taken - 30 minutes, - 15 and - 5 minutes Pre-Dose, then 15, 30 and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, and 10 hours Post-Dose.

    Time frame: From - 30 minutes Pre-Dose to 10 hours Post-Dose

  8. Total Ethanol Dose analyzed by a model independent parameter estimate

    Blood samples for Ethanol concentrations will be taken - 30 minutes, - 15 and - 5 minutes Pre-Dose, then 15, 30 and 60 minutes Post-Dose and then 2, 3, 4, 5, 6, 8, and 10 hours Post-Dose.

    Time frame: From - 30 minutes Pre-Dose to 10 hours Post-Dose

07

Study locations

1 site
  • Leiden, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2012
First posted
Oct 19, 2012
Start
Sep 2012
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Last update
Oct 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01710670
Lead sponsor
UCB Pharma SA
Responsible party
Sponsor
First posted
Oct 19, 2012
Start date
Sep 2012
Primary completion
Nov 2012
Completion
Nov 2012
Last update
Oct 11, 2018

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion